NAD+ Could Slow Aging and Fight Alzheimer's, Early Trials Show

Early findings from clinical trials of NAD+ precursors showed promise for slowing aging and fighting Alzheimer's disease, with some trials reporting improvements in memory, physical movement, and metabolic health. This is significant because Alzheimer's disease has no effective disease-modifying treatment, and NAD+ precursors (NMN, NR) are widely available as supplements. The trials are early-phase, meaning small sample sizes and short durations. The mechanism involves NAD+ depletion in the brain during aging and neurodegeneration, which impairs mitochondrial function and DNA repair. While promising, these are early findings and should not be interpreted as evidence that NAD+ supplements treat or prevent Alzheimer's. The source did not specify which NAD+ precursor was tested, the dose, or the trial design.

NAD+ precursors show early promise in improving memory, physical movement, and metabolic health.